Drug Profile
SD 169
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Scios
- Class Antihyperglycaemics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA
- 25 Jun 2003 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route)